Trial Information

Retrospective Analysis of the Difference of Prognosis Between Unresectable and Recurrent Biliary Tract Cancer

Most patients of biliary tract cancer have advanced disease at diagnosis and often relapse
despite surgery. Combination therapy of gemcitabine and cisplatin could be a standard
therapy for this kind of cancer with the evidence of phase III study compared with
gemcitabine alone. However the prognosis and the tolerability of chemotherapy in the
patients with recurrent biliary tract cancer after radical resection might differ from those
of unresectable biliary tract cancer, because the dose intensity of chemotherapy can be
influenced by adjuvant chemotherapy and/or hepatic resection.